NVCT vs OCS

Nuvectis Pharma, Inc. vs Oculis Holding AG — Valuation Comparison 2026

NVCT

Biotechnology
Nuvectis Pharma, Inc.
Quality
3.8
out of 10
Value Trap
18
SAFE
Price
$10.19
Last close
Models
6/13
Active
VS

OCS

Biotechnology
Oculis Holding AG
Quality
3.8
out of 10
Value Trap
18
SAFE
Price
$29.65
Last close
Models
8/13
Active

Model-by-Model Comparison

ModelType NVCT Fair ValueNVCT Upside OCS Fair ValueOCS Upside
Bayesian DCF Intrinsic $3.24 -68.2% $8.55 -71.2%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $1.15 -88.7% $2.25 -92.4%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for NVCT vs OCS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

NVCT vs OCS — Which Stock Is More Undervalued?

OCS scores higher with a 3.8/10 quality rating vs NVCT's 3.8/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Nuvectis Pharma, Inc. (NVCT) and Oculis Holding AG (OCS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

NVCT currently trades at $10.19 with a QOC of 3.8/10, while OCS trades at $29.65 with a QOC of 3.8/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).